Pasithea Therapeutics Corp. — Director's Dealing 2022

Oct 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-10-17

Reporting Person: Delaney David (Member of 10% owner group)
Reporting Person: Concord IP2 Ltd. (Member of 10% owner group)
Reporting Person: Elderhill Corp (Member of 10% owner group)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-17	Common Stock	P	1000	$1.11	Acquired	227521	Indirect

Footnotes

F1: The shares were purchased by Elderhill Corporation, of which David Delaney serves as sole director and President.

F2: 191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 36,200 shares are held by Elderhill Corporation.